Branchburg, New Jersey (PRWEB) January 04, 2012
ZEUS Scientific announces it has received clearance from the U.S. Food and Drug Administration (FDA) to market the ZEUS ELISA Cardiolipin IgG/IgM/IgA Test System (product number 2Z51051). This new Test System is intended for the in vitro, qualitative measurement of IgG, IgM and/or IgA antibodies directed to cardiolipin in human serum to aid in the diagnosis of primary antiphospholipid syndrome (PAPS) and secondary antiphospholipid syndrome (SAPS) in conjunction with other laboratory and clinical findings.
Many ZEUS ELISA Test Systems use a common procedure and share several common reagents, making automation simple and efficient. This allows laboratories to run multiple tests on the same plate, at the same time maximizing ELISA run efficiency and minimizing workflow. In addition, ZEUS ELISA Test Systems include patented SAVe™ Diluent, a Sample Addition Verification system designed to clearly identify patient sera is added to each and every well.
ZEUS Scientific also markets three individual cardiolipin ELISA test systems measuring antibodies in patient serum for IgG (part number 2Z51051G) or IgM (part number 2Z51051M) or IgA (2Z51051M) class antibodies. The combination of all four ZEUS ELISA Cardiolipin Test Systems allows laboratories the flexibility to test for cardiolipin antibodies in the manner they prefer – individually or combined in one microwell.
ZEUS Scientific also markets numerous immunofluorescence assays (ZEUS IFA) and multiplex immunoassays (AtheNA Multi-Lyte™ Test Systems) to the clinical marketplace for both autoimmune disease and infectious serology tests. For a complete listing of all ZEUS Scientific in vitro diagnostic test systems, please visit http://www.zeusscientific.com/products/. The ZEUS ELISA Cardiolipin IgG/IgM/IgA Test System and all other products are available for sale through the global ZEUS Scientific distribution network. Please visit http://www.zeusscientific.com to locate your local distributor.